Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-18-003419)

Filing Details

Accession Number:: 0001209191-18-003419
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-01-12 16:16:17
Reporting Period:: 2018-01-11

Accepted Time:: 2018-01-12 16:16:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557290	A Stuart Arbuckle	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp\Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-01-11	4,250	$109.14	46,202	No	4	M	Direct
Common Stock	Disposition	2018-01-11	4,250	$159.00	41,952	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-01-11	4,250	$0.00	4,250	$109.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
21,250		2025-02-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	140	Indirect	401(k)

Footnotes

Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
The option vests in 16 quarterly installments from 02/03/2015.